全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

A Novel Opportunity in Minimally Invasive Colorectal Cancer Therapy: Defining a Role for Endoscopic Submucosal Dissection in the United States

DOI: 10.1155/2013/681783

Full-Text   Cite this paper   Add to My Lib

Abstract:

Colorectal cancer is the third most common cancer among both men and women in the United States and the second leading cause of cancer death. Endoscopic submucosal dissection (ESD) is an innovative advanced endoscopic therapy for superficial gastrointestinal neoplasms which is rapidly becoming standard of care particularly in Asia. ESD was first developed for the resection of early gastric cancers; yet ESD for colon tumors has gained increasing attention in recent years. The advantage of ESD over conventional endoscopic resection lies in its potential to achieve en bloc resection regardless of tumor size, leading to more precise histological evaluation and greater potential for cure. Selecting appropriate patients for this procedure involves identifying colorectal cancers with nul risk of lymph node spread. For colorectal ESD to engraft in the United States, the prevalence of such early stage lesions must be defined so that centers of excellence can be developed for high volume clinical practice to offer patients the safest and most efficacious outcomes. This review discusses the endoscopic staging of colorectal neoplasms, indications for colorectal ESD, and the epidemiology of early stage ESD-amenable colorectal cancer in America to better define an opportunity for this important minimally invasive therapy. 1. Introduction: Endoscopic Submucosal Dissection and Colorectal Neoplasia Cancers of the colon and rectum are the third most common cancers among both men and women in the United States and the second leading cause of cancer death [1]. Endoscopic submucosal dissection (ESD) is an innovative advanced endoscopic approach to superficial gastrointestinal neoplasms, which is becoming the standard treatment, particularly in advanced Asian medical centers [2, 3]. ESD was first utilized in the resection of early gastric neoplasms; yet ESD for colon tumors has gained increasing attention in recent years [4–9]. The advantage of ESD over conventional endoscopic mucosal resection is that it has the potential for a high rate of en bloc resection regardless of tumor size, leading to precise histological evaluation of the specimen margins and a lower recurrence rate at long-term followup [5, 10–12]. In one of the largest follow-up studies to date evaluating ESD for colorectal epithelial neoplasms including both adenomas and carcinomas, the 5-year overall/disease-specific survival was greater than 95% [10]. In an analysis of several studies totaling greater than 700 cases of ESD for colorectal cancer, local recurrence rates averaged approximately 1% [7]. Finally,

References

[1]  P. H. Levine, S. C. Steinhorn, L. Gloeckler Ries, and J. L. Aron, “Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program,” Journal of the National Cancer Institute, vol. 74, no. 2, pp. 291–297, 1985.
[2]  S. Kiriyama, Y. Saito, S. Yamamoto, R. Soetikno, T. Matsuda, T. Nakajima, et al., “Comparison of endoscopic submucosal dissection with laparoscopic-assisted colorectal surgery for early-stage colorectal cancer: a retrospective analysis,” Endoscopy, vol. 44, no. 11, pp. 1024–1030, 2012.
[3]  S. U. Park, Y. W. Min, J. U. Shin, J. H. Choi, Y. H. Kim, J. J. Kim, et al., “Endoscopic submucosal dissection or transanal endoscopic microsurgery for nonpolypoid rectal high grade dysplasia and submucosa-invading rectal cancer,” Endoscopy, vol. 44, no. 11, pp. 1031–1036, 2012.
[4]  C. Huang, R. X. Huang, P. Xiang, and Z. J. Qiu, “Current research status of endoscopic submucosal dissection for colorectal neoplasms,” Clinical and Investigative Medicine Medecine Clinique Et Experimentale, vol. 35, pp. E158–E164, 2012.
[5]  Y. Saito, T. Uraoka, T. Matsuda et al., “Endoscopic treatment of large superficial colorectal tumors: a case series of 200 endoscopic submucosal dissections (with video),” Gastrointestinal Endoscopy, vol. 66, no. 5, pp. 966–973, 2007.
[6]  E.-J. Lee, J. B. Lee, S. H. Lee, and E. G. Youk, “Endoscopic treatment of large colorectal tumors: comparison of endoscopic mucosal resection, endoscopic mucosal resection-precutting, and endoscopic submucosal dissection,” Surgical Endoscopy, vol. 26, pp. 2220–2230, 2012.
[7]  S. Tanaka, M. Terasaki, H. Kanao, S. Oka, and K. Chayama, “Current status and future perspectives of endoscopic submucosal dissection for colorectal tumors,” Digestive Endoscopy, vol. 24, no. 1, pp. 73–79, 2012.
[8]  S. Tanaka, S. Oka, I. Kaneko et al., “Endoscopic submucosal dissection for colorectal neoplasia: possibility of standardization,” Gastrointestinal Endoscopy, vol. 66, no. 1, pp. 100–107, 2007.
[9]  T. Uraoka, A. Parra-Blanco, and N. Yahagi, “Colorectal endoscopic submucosal dissection in Japan and Western countries,” Digestive Endoscopy, vol. 24, no. 1, pp. 80–83, 2012.
[10]  K. Niimi, M. Fujishiro, S. Kodashima et al., “Long-term outcomes of endoscopic submucosal dissection for colorectal epithelial neoplasms,” Endoscopy, vol. 42, no. 9, pp. 723–729, 2010.
[11]  Y. Saito, T. Uraoka, Y. Yamaguchi et al., “A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video),” Gastrointestinal Endoscopy, vol. 72, no. 6, pp. 1217–1225, 2010.
[12]  A. Repici, C. Hassan, D. De Paula Pessoa et al., “Efficacy and safety of endoscopic submucosal dissection for colorectal neoplasia: a systematic review,” Endoscopy, vol. 44, no. 2, pp. 137–150, 2012.
[13]  Y. Yoda, H. Ikematsu, T. Matsuda, Y. Yamaguchi, K. Hotta, N. Kobayashi, et al., “A large-scale multicenter study of long-term outcomes after endoscopic resection for submucosal invasive colorectal cancer,” Endoscopy, vol. 45, no. 9, pp. 718–724, 2013.
[14]  L. L. Swanstrom, “Treatment of early colorectal cancers: too many choices?” Endoscopy, vol. 44, no. 11, pp. 991–992, 2012.
[15]  S. V. Kantsevoy, D. G. Adler, J. D. Conway et al., “Endoscopic mucosal resection and endoscopic submucosal dissection,” Gastrointestinal Endoscopy, vol. 68, no. 1, pp. 11–18, 2008.
[16]  R. C. Haggitt, R. E. Glotzbach, E. E. Soffer, and L. D. Wruble, “Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy,” Gastroenterology, vol. 89, no. 2, pp. 328–336, 1985.
[17]  “The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002,” Gastrointestinal Endoscopy, vol. 58, supplement 6, pp. S3–S43, 2003.
[18]  S.-F. Huang, “The World Health Organization and the Vienna classification of gastrointestinal epithelial neoplasia,” Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology, vol. 34, no. 8, pp. 540–541, 2005.
[19]  S.-E. Kudo, H. Kashida, T. Nakajima, S. Tamura, and K. Nakajo, “Endoscopic diagnosis and treatment of early colorectal cancer,” World Journal of Surgery, vol. 21, no. 7, pp. 694–701, 1997.
[20]  H. Yanai, Y. Matsumoto, T. Harada et al., “Endoscopic ultrasonography and endoscopy for staging depth of invasion in early gastric cancer: a pilot study,” Gastrointestinal Endoscopy, vol. 46, no. 3, pp. 212–216, 1997.
[21]  S. Kudo, H. Kashida, S. Tamura, and T. Nakajima, “The problem of 'flat' colonic adenoma,” Gastrointestinal Endoscopy Clinics of North America, vol. 7, no. 1, pp. 87–98, 1997.
[22]  A. Yokoyama, H. Watanabe, and Y. Asakura, “Lymph node metastasis and micrometastasis of submucosal invasive colorectal carcinoma: an indicator of the curative potential of endoscopic treatment,” Acta Medica Et Biologica, vol. 50, no. 1, pp. 1–8, 2002.
[23]  K. Kitajima, T. Fujimori, S. Fuji et al., “Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study,” Journal of Gastroenterology, vol. 39, no. 6, pp. 534–543, 2004.
[24]  T. Watanabe, M. Itabashi, Y. Shimada et al., “Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer,” International Journal of Clinical Oncology, vol. 17, pp. 1–29, 2011.
[25]  T. Watanabe, M. Itabashi, Y. Shimada, et al., “Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer,” International Journal of Clinical Oncology, vol. 17, no. 1, pp. 1–29, 2012.
[26]  S. L. Bosch, S. Teerenstra, J. H. de Wilt, C. Cunningham, and I. D. Nagtegaal, “Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions,” Endoscopy, vol. 45, no. 10, pp. 827–841, 2013.
[27]  N. Hayashi, S. Tanaka, D. G. Hewett, T. R. Kaltenbach, Y. Sano, T. Ponchon, et al., “Endoscopic prediction of deep submucosal invasive carcinoma: validation of the Narrow-Band Imaging International Colorectal Endoscopic (NICE) classification,” Gastrointestinal Endoscopy, vol. 78, pp. 625–632, 2013.
[28]  S. Tanaka, S. Oka, and K. Chayama, “Colorectal endoscopic submucosal dissection: present status and future perspective, including its differentiation from endoscopic mucosal resection,” Journal of Gastroenterology, vol. 43, no. 9, pp. 641–651, 2008.
[29]  S. Tanaka, Y. Tamegai, S. Tsuda, Y. Saito, N. Yahagi, and H.-O. Yamano, “Multicenter questionnaire survey on the current situation of colorectal endoscopic submucosal dissection in Japan,” Digestive Endoscopy, vol. 22, no. 1, pp. S2–S8, 2010.
[30]  S. B. Edge and C. C. Compton, “The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM,” Annals of Surgical Oncology, vol. 17, no. 6, pp. 1471–1474, 2010.
[31]  R. Nascimbeni, L. J. Burgart, S. Nivatvongs, and D. R. Larson, “Risk of lymph node metastasis in T1 carcinoma of the colon and rectum,” Diseases of the Colon and Rectum, vol. 45, no. 2, pp. 200–206, 2002.
[32]  W.-L. Fang, S.-C. Chang, J.-K. Lin et al., “Metastatic potential in T1 and T2 colorectal cancer,” Hepato-Gastroenterology, vol. 52, no. 66, pp. 1688–1691, 2005.
[33]  S. Yamamoto, M. Watanabe, H. Hasegawa et al., “The risk of lymph node metastasis in T1 colorectal carcinoma,” Hepato-Gastroenterology, vol. 51, no. 58, pp. 998–1000, 2004.
[34]  A. Carrara, D. Mangiola, R. Pertile, A. Ricci, M. Motter, G. Ghezzi, et al., “Analysis of risk factors for lymph nodal involvement in early stages of rectal cancer: when can local excision be considered an appropriate treatment? Systematic review and meta-analysis of the literature,” International Journal of Surgical Oncology, vol. 2012, Article ID 438450, 8 pages, 2012.
[35]  J. B. O'Connell, M. A. Maggard, and C. Y. Ko, “Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging,” Journal of the National Cancer Institute, vol. 96, no. 19, pp. 1420–1425, 2004.
[36]  H. Bang, “Medical cost analysis: application to colorectal cancer data from the SEER Medicare database,” Contemporary Clinical Trials, vol. 26, no. 5, pp. 586–597, 2005.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133